Review



mapk inhibitor sb202190  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    MedChemExpress mapk inhibitor sb202190
    Mapk Inhibitor Sb202190, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 118 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitor sb202190/product/MedChemExpress
    Average 95 stars, based on 118 article reviews
    mapk inhibitor sb202190 - by Bioz Stars, 2026-02
    95/100 stars

    Images



    Similar Products

    95
    MedChemExpress mapk inhibitor sb202190
    Mapk Inhibitor Sb202190, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitor sb202190/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    mapk inhibitor sb202190 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress p38 mapk specific inhibitor sb202190
    BMDCs were pretreated with control culture, Nets, OVA/LPS, OVA/LPS/Nets and then coculture with naïve CD4 + T lymphocytes. a. Representative flow cytometric analysis and comparisons of Th17 in each group. b Comparisons of concentrations of IL-17 in each group. c. Comparisons of concentrations of IL-6 in each group, d. Comparisons of concentrations of IL-23 in each group. e. Representative Western blot images and comparisons of <t>p-p38/p38</t> MAPK, p-IKBα/IKBα, p65/p65, β-actin in each group. f. The images of immunohistochemical staining and comparisons for <t>P-p38</t> <t>MAPK,</t> P-pIKBα, P-p65 expression in the CD11c+ positive cells of CON and OVA/LPS induced lung, (P-p38 in the lung were identified with DAPI (blue), P-p38 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-p65 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-pIKBα (red) and CD11c+ (green) by confocal microscopy). OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, p38 inhibitor <t>(SB202190),</t> OVA/LPS/Nets/SB202190, and then coculture with naïve CD4 + T lymphocytes, g. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p65/p65, β-actin. in each group, h. Comparisons of concentrations of IL-6 in each group, i. Comparisons of concentrations of IL-23 in each group. OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, NF-κB inhibitor (DHMEQ), OVA/LPS/Nets/DHMEQ, and then coculture with naïve CD4 + T lymphocytes, j. Representative Western blot images and comparisons of p-IKBα/IKBα, p65/p65, β-actin in each group, k. Comparisons of concentrations of IL-6 in each group, l. Comparisons of concentrations of IL-23 in each group. m. Representative flow cytometric analysis and comparisons of Th17 in CON, OLN, SB202190, OLNS group. n. Comparisons of concentrations of IL-17 in in CON, OLN, SB202190, OLNS group. o. Representative flow cytometric analysis and comparisons of Th17 in in CON, OLN, DHMEQ, OLND group. p Comparisons of concentrations of IL-17 in each group. (Data were means ± SEM (n = 3); * * P < 0.01) (CON: control group, Nets: Neutrophil extracellular traps group, OL: OVA/LPS group, OLN:OVA/LPS/Nets group, SB202190:a <t>p38-MAPK</t> specific inhibitor group, DHMEQ: a NF-κB-specific inhibitor group, OLNS:OVA/LPS/Nets/SB202190 group, OLND:OVA/LPS/Nets/DHMEQ group).
    P38 Mapk Specific Inhibitor Sb202190, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p38 mapk specific inhibitor sb202190/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    p38 mapk specific inhibitor sb202190 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    90
    GlpBio Technology Inc selective p38 mapk inhibitor sb202190
    BMDCs were pretreated with control culture, Nets, OVA/LPS, OVA/LPS/Nets and then coculture with naïve CD4 + T lymphocytes. a. Representative flow cytometric analysis and comparisons of Th17 in each group. b Comparisons of concentrations of IL-17 in each group. c. Comparisons of concentrations of IL-6 in each group, d. Comparisons of concentrations of IL-23 in each group. e. Representative Western blot images and comparisons of <t>p-p38/p38</t> MAPK, p-IKBα/IKBα, p65/p65, β-actin in each group. f. The images of immunohistochemical staining and comparisons for <t>P-p38</t> <t>MAPK,</t> P-pIKBα, P-p65 expression in the CD11c+ positive cells of CON and OVA/LPS induced lung, (P-p38 in the lung were identified with DAPI (blue), P-p38 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-p65 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-pIKBα (red) and CD11c+ (green) by confocal microscopy). OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, p38 inhibitor <t>(SB202190),</t> OVA/LPS/Nets/SB202190, and then coculture with naïve CD4 + T lymphocytes, g. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p65/p65, β-actin. in each group, h. Comparisons of concentrations of IL-6 in each group, i. Comparisons of concentrations of IL-23 in each group. OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, NF-κB inhibitor (DHMEQ), OVA/LPS/Nets/DHMEQ, and then coculture with naïve CD4 + T lymphocytes, j. Representative Western blot images and comparisons of p-IKBα/IKBα, p65/p65, β-actin in each group, k. Comparisons of concentrations of IL-6 in each group, l. Comparisons of concentrations of IL-23 in each group. m. Representative flow cytometric analysis and comparisons of Th17 in CON, OLN, SB202190, OLNS group. n. Comparisons of concentrations of IL-17 in in CON, OLN, SB202190, OLNS group. o. Representative flow cytometric analysis and comparisons of Th17 in in CON, OLN, DHMEQ, OLND group. p Comparisons of concentrations of IL-17 in each group. (Data were means ± SEM (n = 3); * * P < 0.01) (CON: control group, Nets: Neutrophil extracellular traps group, OL: OVA/LPS group, OLN:OVA/LPS/Nets group, SB202190:a <t>p38-MAPK</t> specific inhibitor group, DHMEQ: a NF-κB-specific inhibitor group, OLNS:OVA/LPS/Nets/SB202190 group, OLND:OVA/LPS/Nets/DHMEQ group).
    Selective P38 Mapk Inhibitor Sb202190, supplied by GlpBio Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/selective p38 mapk inhibitor sb202190/product/GlpBio Technology Inc
    Average 90 stars, based on 1 article reviews
    selective p38 mapk inhibitor sb202190 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    95
    MedChemExpress p38 mapk signaling pathway inhibitor sb202190
    BMDCs were pretreated with control culture, Nets, OVA/LPS, OVA/LPS/Nets and then coculture with naïve CD4 + T lymphocytes. a. Representative flow cytometric analysis and comparisons of Th17 in each group. b Comparisons of concentrations of IL-17 in each group. c. Comparisons of concentrations of IL-6 in each group, d. Comparisons of concentrations of IL-23 in each group. e. Representative Western blot images and comparisons of <t>p-p38/p38</t> MAPK, p-IKBα/IKBα, p65/p65, β-actin in each group. f. The images of immunohistochemical staining and comparisons for <t>P-p38</t> <t>MAPK,</t> P-pIKBα, P-p65 expression in the CD11c+ positive cells of CON and OVA/LPS induced lung, (P-p38 in the lung were identified with DAPI (blue), P-p38 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-p65 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-pIKBα (red) and CD11c+ (green) by confocal microscopy). OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, p38 inhibitor <t>(SB202190),</t> OVA/LPS/Nets/SB202190, and then coculture with naïve CD4 + T lymphocytes, g. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p65/p65, β-actin. in each group, h. Comparisons of concentrations of IL-6 in each group, i. Comparisons of concentrations of IL-23 in each group. OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, NF-κB inhibitor (DHMEQ), OVA/LPS/Nets/DHMEQ, and then coculture with naïve CD4 + T lymphocytes, j. Representative Western blot images and comparisons of p-IKBα/IKBα, p65/p65, β-actin in each group, k. Comparisons of concentrations of IL-6 in each group, l. Comparisons of concentrations of IL-23 in each group. m. Representative flow cytometric analysis and comparisons of Th17 in CON, OLN, SB202190, OLNS group. n. Comparisons of concentrations of IL-17 in in CON, OLN, SB202190, OLNS group. o. Representative flow cytometric analysis and comparisons of Th17 in in CON, OLN, DHMEQ, OLND group. p Comparisons of concentrations of IL-17 in each group. (Data were means ± SEM (n = 3); * * P < 0.01) (CON: control group, Nets: Neutrophil extracellular traps group, OL: OVA/LPS group, OLN:OVA/LPS/Nets group, SB202190:a <t>p38-MAPK</t> specific inhibitor group, DHMEQ: a NF-κB-specific inhibitor group, OLNS:OVA/LPS/Nets/SB202190 group, OLND:OVA/LPS/Nets/DHMEQ group).
    P38 Mapk Signaling Pathway Inhibitor Sb202190, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p38 mapk signaling pathway inhibitor sb202190/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    p38 mapk signaling pathway inhibitor sb202190 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals p38 mapk inhibitor p38i
    Media to grow the colon human organoids (Organoid expansion medium)
    P38 Mapk Inhibitor P38i, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p38 mapk inhibitor p38i/product/Selleck Chemicals
    Average 96 stars, based on 1 article reviews
    p38 mapk inhibitor p38i - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    90
    STEMCELL Technologies Inc sb202190 p38 mapk inhibitor stem cell 72632
    Media to grow the colon human organoids (Organoid expansion medium)
    Sb202190 P38 Mapk Inhibitor Stem Cell 72632, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sb202190 p38 mapk inhibitor stem cell 72632/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    sb202190 p38 mapk inhibitor stem cell 72632 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    STEMCELL Technologies Inc p38 mapk specific inhibitor sb202190
    Media to grow the colon human organoids (Organoid expansion medium)
    P38 Mapk Specific Inhibitor Sb202190, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p38 mapk specific inhibitor sb202190/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    p38 mapk specific inhibitor sb202190 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    90
    STEMCELL Technologies Inc inhibitors targeting the p38 mapk pathway #sb202190
    Media to grow the colon human organoids (Organoid expansion medium)
    Inhibitors Targeting The P38 Mapk Pathway #Sb202190, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/inhibitors targeting the p38 mapk pathway #sb202190/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    inhibitors targeting the p38 mapk pathway #sb202190 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    BMDCs were pretreated with control culture, Nets, OVA/LPS, OVA/LPS/Nets and then coculture with naïve CD4 + T lymphocytes. a. Representative flow cytometric analysis and comparisons of Th17 in each group. b Comparisons of concentrations of IL-17 in each group. c. Comparisons of concentrations of IL-6 in each group, d. Comparisons of concentrations of IL-23 in each group. e. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p65/p65, β-actin in each group. f. The images of immunohistochemical staining and comparisons for P-p38 MAPK, P-pIKBα, P-p65 expression in the CD11c+ positive cells of CON and OVA/LPS induced lung, (P-p38 in the lung were identified with DAPI (blue), P-p38 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-p65 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-pIKBα (red) and CD11c+ (green) by confocal microscopy). OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, p38 inhibitor (SB202190), OVA/LPS/Nets/SB202190, and then coculture with naïve CD4 + T lymphocytes, g. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p65/p65, β-actin. in each group, h. Comparisons of concentrations of IL-6 in each group, i. Comparisons of concentrations of IL-23 in each group. OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, NF-κB inhibitor (DHMEQ), OVA/LPS/Nets/DHMEQ, and then coculture with naïve CD4 + T lymphocytes, j. Representative Western blot images and comparisons of p-IKBα/IKBα, p65/p65, β-actin in each group, k. Comparisons of concentrations of IL-6 in each group, l. Comparisons of concentrations of IL-23 in each group. m. Representative flow cytometric analysis and comparisons of Th17 in CON, OLN, SB202190, OLNS group. n. Comparisons of concentrations of IL-17 in in CON, OLN, SB202190, OLNS group. o. Representative flow cytometric analysis and comparisons of Th17 in in CON, OLN, DHMEQ, OLND group. p Comparisons of concentrations of IL-17 in each group. (Data were means ± SEM (n = 3); * * P < 0.01) (CON: control group, Nets: Neutrophil extracellular traps group, OL: OVA/LPS group, OLN:OVA/LPS/Nets group, SB202190:a p38-MAPK specific inhibitor group, DHMEQ: a NF-κB-specific inhibitor group, OLNS:OVA/LPS/Nets/SB202190 group, OLND:OVA/LPS/Nets/DHMEQ group).

    Journal: PLOS One

    Article Title: Xiao Qing Long Tang ameliorates neutrophil extracellular trap-dendritic cells-T helper 17 cell axis in Neutrophilic Asthma

    doi: 10.1371/journal.pone.0336333

    Figure Lengend Snippet: BMDCs were pretreated with control culture, Nets, OVA/LPS, OVA/LPS/Nets and then coculture with naïve CD4 + T lymphocytes. a. Representative flow cytometric analysis and comparisons of Th17 in each group. b Comparisons of concentrations of IL-17 in each group. c. Comparisons of concentrations of IL-6 in each group, d. Comparisons of concentrations of IL-23 in each group. e. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p65/p65, β-actin in each group. f. The images of immunohistochemical staining and comparisons for P-p38 MAPK, P-pIKBα, P-p65 expression in the CD11c+ positive cells of CON and OVA/LPS induced lung, (P-p38 in the lung were identified with DAPI (blue), P-p38 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-p65 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-pIKBα (red) and CD11c+ (green) by confocal microscopy). OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, p38 inhibitor (SB202190), OVA/LPS/Nets/SB202190, and then coculture with naïve CD4 + T lymphocytes, g. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p65/p65, β-actin. in each group, h. Comparisons of concentrations of IL-6 in each group, i. Comparisons of concentrations of IL-23 in each group. OVA/LPS/Nets-stimulated BMDCs were pretreated with control culture, OVA/LPS/Nets, NF-κB inhibitor (DHMEQ), OVA/LPS/Nets/DHMEQ, and then coculture with naïve CD4 + T lymphocytes, j. Representative Western blot images and comparisons of p-IKBα/IKBα, p65/p65, β-actin in each group, k. Comparisons of concentrations of IL-6 in each group, l. Comparisons of concentrations of IL-23 in each group. m. Representative flow cytometric analysis and comparisons of Th17 in CON, OLN, SB202190, OLNS group. n. Comparisons of concentrations of IL-17 in in CON, OLN, SB202190, OLNS group. o. Representative flow cytometric analysis and comparisons of Th17 in in CON, OLN, DHMEQ, OLND group. p Comparisons of concentrations of IL-17 in each group. (Data were means ± SEM (n = 3); * * P < 0.01) (CON: control group, Nets: Neutrophil extracellular traps group, OL: OVA/LPS group, OLN:OVA/LPS/Nets group, SB202190:a p38-MAPK specific inhibitor group, DHMEQ: a NF-κB-specific inhibitor group, OLNS:OVA/LPS/Nets/SB202190 group, OLND:OVA/LPS/Nets/DHMEQ group).

    Article Snippet: To explore the signaling pathways involved in OVA/LPS/Nets-induced BMDCs in regulating Th17 cell differentiation, BMDCs were pre-treated with specific inhibitors: 10 μM p38-MAPK specific inhibitor SB202190(MCE, USA, HY-10295) and 5 μg/ml NF-κB-specific inhibitor DHMEQ (MCE, USA, HY-14645) 1 hour before being stimulated with OVA/LPS/Nets.

    Techniques: Control, Western Blot, Immunohistochemical staining, Staining, Expressing, Confocal Microscopy

    BMDCs were pretreated with control culture (CON), OVA/LPS/Nets (OLN), XQLT, OVA/LPS/Nets/XQLT(OLNX) and then coculture with naïve CD4 + T lymphocytes. a. comparisons of concentrations of IL-6 in each group, b. comparisons of concentrations of IL-23 in each group, c. Representative flow cytometric analysis and comparisons of Th17 cells in each group, d. Comparisons of concentrations of IL-17 in each group, f. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p-p65/p65, β-actin in each group, f. The images of immunohistochemical staining and comparisons for P-p38 MAPK, P-pIKBα, P-p65 expression in the CD11c+ positive cells of lung, (P-p38 in the lung were identified with DAPI (blue), P-p38 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-p65 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-pIKBα (red) and CD11c+ (green) by confocal microscopy) (Data are means ± SEM (n = 3); ** P < 0.01) (CON: control group, XQLT: Xiao Qing Long Tang group, OLN: OVA/LPS/Nets group, OLNX:OVA/LPS/Nets/XQLT group).

    Journal: PLOS One

    Article Title: Xiao Qing Long Tang ameliorates neutrophil extracellular trap-dendritic cells-T helper 17 cell axis in Neutrophilic Asthma

    doi: 10.1371/journal.pone.0336333

    Figure Lengend Snippet: BMDCs were pretreated with control culture (CON), OVA/LPS/Nets (OLN), XQLT, OVA/LPS/Nets/XQLT(OLNX) and then coculture with naïve CD4 + T lymphocytes. a. comparisons of concentrations of IL-6 in each group, b. comparisons of concentrations of IL-23 in each group, c. Representative flow cytometric analysis and comparisons of Th17 cells in each group, d. Comparisons of concentrations of IL-17 in each group, f. Representative Western blot images and comparisons of p-p38/p38 MAPK, p-IKBα/IKBα, p-p65/p65, β-actin in each group, f. The images of immunohistochemical staining and comparisons for P-p38 MAPK, P-pIKBα, P-p65 expression in the CD11c+ positive cells of lung, (P-p38 in the lung were identified with DAPI (blue), P-p38 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-p65 (red) and CD11c+ (green) by confocal microscopy, P-p65 in the lung were identified with DAPI (blue), P-pIKBα (red) and CD11c+ (green) by confocal microscopy) (Data are means ± SEM (n = 3); ** P < 0.01) (CON: control group, XQLT: Xiao Qing Long Tang group, OLN: OVA/LPS/Nets group, OLNX:OVA/LPS/Nets/XQLT group).

    Article Snippet: To explore the signaling pathways involved in OVA/LPS/Nets-induced BMDCs in regulating Th17 cell differentiation, BMDCs were pre-treated with specific inhibitors: 10 μM p38-MAPK specific inhibitor SB202190(MCE, USA, HY-10295) and 5 μg/ml NF-κB-specific inhibitor DHMEQ (MCE, USA, HY-14645) 1 hour before being stimulated with OVA/LPS/Nets.

    Techniques: Control, Western Blot, Immunohistochemical staining, Staining, Expressing, Confocal Microscopy

    Media to grow the colon human organoids (Organoid expansion medium)

    Journal: STAR Protocols

    Article Title: Protocol for functional screening of CFTR -targeted genetic therapies in patient-derived organoids using DETE CT OR deep-learning-based analysis

    doi: 10.1016/j.xpro.2024.103593

    Figure Lengend Snippet: Media to grow the colon human organoids (Organoid expansion medium)

    Article Snippet: p38 MAPK inhibitor (p38i) (SB202190) , Selleckchem , S1077 , 100 mM , 0.5 mL , 10 mM.

    Techniques: Concentration Assay